$-0.19 EPS Expected for Endocyte, Inc. (ECYT)

July 14, 2018 - By Kyle Williams

Investors sentiment increased to 2.32 in Q1 2018. Its up 0.96, from 1.36 in 2017Q4. It improved, as 10 investors sold Endocyte, Inc. shares while 12 reduced holdings. 27 funds opened positions while 24 raised stakes. 41.55 million shares or 108.70% more from 19.91 million shares in 2017Q4 were reported.
40,000 were accumulated by Hancock Holdings. Bb&T Ltd Liability Company, a Virginia-based fund reported 20,750 shares. Ra Management Limited Liability Com holds 2.7% or 3.88 million shares in its portfolio. Captrust Fincl Advisors invested in 400 shares or 0% of the stock. 52,512 were accumulated by Bankshares Of Ny Mellon. First Fincl Corp In holds 100 shares or 0% of its portfolio. Panagora Asset holds 12,240 shares or 0% of its portfolio. Renaissance Technologies Limited Co invested in 0% or 194,500 shares. Rock Springs Capital Limited Partnership invested in 675,000 shares or 0.26% of the stock. Baker Bros Limited Partnership owns 0.18% invested in Endocyte, Inc. (NASDAQ:ECYT) for 2.28M shares. Blackrock Incorporated owns 1.71M shares for 0% of their portfolio. Bluecrest owns 0.05% invested in Endocyte, Inc. (NASDAQ:ECYT) for 171,019 shares. Geode owns 384,782 shares. 19,300 are held by Jacobs Levy Equity. Tower Rech Capital Lc (Trc) owns 0.01% invested in Endocyte, Inc. (NASDAQ:ECYT) for 16,343 shares.

Since March 9, 2018, it had 0 insider buys, and 2 insider sales for $242,735 activity.

Analysts expect Endocyte, Inc. (NASDAQ:ECYT) to report $-0.19 EPS on August, 14.They anticipate $0.09 EPS change or 32.14 % from last quarter’s $-0.28 EPS. After having $-0.16 EPS previously, Endocyte, Inc.’s analysts see 18.75 % EPS growth. The stock decreased 0.35% or $0.06 during the last trading session, reaching $17.26. About 503,744 shares traded. Endocyte, Inc. (NASDAQ:ECYT) has risen 444.08% since July 14, 2017 and is uptrending. It has outperformed by 431.51% the S&P500.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

Among 3 analysts covering Endocyte (NASDAQ:ECYT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endocyte had 3 analyst reports since February 27, 2018 according to SRatingsIntel. The stock of Endocyte, Inc. (NASDAQ:ECYT) earned “Outperform” rating by Cowen & Co on Tuesday, February 27.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company has market cap of $1.20 billion. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents. It currently has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

More important recent Endocyte, Inc. (NASDAQ:ECYT) news were published by: Globenewswire.com which released: “Endocyte to Join the Russell 3000® Index” on June 25, 2018, also Seekingalpha.com published article titled: “Rounds Report: Endocyte Rallied While The Tricida IPO Was A Success”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering” on July 13, 2018. More interesting news about Endocyte, Inc. (NASDAQ:ECYT) was released by: Fool.com and their article: “3 Huge Biotech Winners in 2018 (So Far)” with publication date: July 11, 2018.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.